RESEARCH TRIANGLE PARK, N.C. – June 2, 2014 – Quintiles, the world’s largest biopharmaceutical services provider, has been named to the Fortune 500 list of largest U.S. companies ranked by revenue.

“Being named to the Fortune 500 is a significant milestone in Quintiles’ history,” said CEO Tom Pike. “We operated as a private company for a full decade before returning to the public markets via IPO in 2013. Our inclusion in the Fortune 500 is another indicator that Quintiles is one of the most important companies headquartered in the United States, conducting business in 100 countries.

“Quintiles’ management and our 29,000-plus employees around the world take great pride in what this accomplishment says about the impact and forward thinking of this company,” Pike continued. “We come to work every day seeking to help patients and improve our customers’ probability of success. Joining the Fortune 500 is evidence that we are indeed on the right path.”

Companies considered for the Fortune 500 are ranked by total revenues for their respective fiscal years. Included in the survey are companies that are incorporated in the U.S. and operate in the U.S. and file financial statements with a government agency.

The full FORTUNE 500 list and related stories appear in the magazine’s June 16 issue and at

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 29,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit


Phil Bridges, Media Relations (
+ 1.919.998.1653 (office) +1.919.457.6347 (mobile)

Karl Deonanan, Investor Relations (